AstraZeneca has reported an increase of revenue of 41% (38 at CER) to $37,417 million in results for the year 2021 released on Thursday. This includes revenue from COVID-19 vaccine of $3,981 million. The increase of revenue has been driven by five medicines: Tagrisso ($5bn+), Farxiga ($3bn+), Lynparza ($2bn+), Calquence ($1bn+) and Fasenra ($1bn+).
In 2021 AstraZeneca completed the acquisition of Alexion which resulted in rare disease medicines revenue of $3,071milion or 8% of total revenue.
The R&D expenses have increased by 62% due to 14 positive Phase III readouts in 2021, the addition of Alexion R&D and COVID-19 medicines investment, and pharmacovigilance.
Also, G&A expenses have increased by 35% due to the addition of Alexion and expansion in emerging markets which resulted in a 41% increase of revenue in emerging markets to $12,281million of which $2,304m came from COVID-19 vaccine Vaxzevria.
Earnings per share in 2021 is $0.08 which is a 97% decline compared to last year’s $2.44.
The company also announced that the Board intends to increase the annualized dividend by $0.10 to $2.90, and has approved a second interim dividend for FY 2021 of $1.97, payable in March 2022. This results in a total dividend declared for FY 2021 of $2.87.